Alex Sirois

Alex Sirois

InvestorPlace Contributor

Alex is a freelance contributor to InvestorPlace who provides investment insight that is conversational, actionable, and educational. While he writes about all stock classes, his personal stock investing style is focused on long-term, buy-and-hold, wealth-building stock picks.

Having worked in several industries from e-commerce to translation to education and utilizing his MBA from George Washington University, he brings a diverse set of skills through which he filters his writing. His number one goal in writing for InvestorPlace is to bring value to the reader.

You can follow Alex on LinkedIn.

Recent Articles

Ocugen Just Overcame a Serious Hurdle

By Alex Sirois, InvestorPlace Contributor

OCGN stock has skyrocketed on positive Phase 3 results. But the company is facing tough competition.

7 Great Dividend Stocks Outside the Energy Sector

By Alex Sirois, InvestorPlace Contributor

Dividend stocks come in many flavors although investors may associate them primarily with the energy sector. These seven stocks cross industries.

Why Investors Should Avoid OrganiGram

By Alex Sirois, InvestorPlace Contributor

OGI stock has risen meteorically. No one should buy the shares now, as OrganiGram has obvious operational issues.

Bionano Genomics Would Have Been a Great Find Months Ago

By Alex Sirois, InvestorPlace Contributor

BNGO stock shot up massively in the past few months. Now isn't the time to invest as the company must first prove its technology sells.

Gevo Is on the Right Track But Shares Are Overvalued

By Alex Sirois, InvestorPlace Contributor

GEVO stock is headed in the right direction in a sector with growth ahead. That said, investors should tread carefully now.

Load More